UK Health Security Agency says early flu rise has slowed


Flu and COVID-19 remain at low levels, the agency says. It plans to track respiratory viruses throughout winter.
The early rise in flu has slowed, and both flu and COVID-19 remain at low levels, the UK Health Security Agency (UKHSA) said on 15 October. Consultant epidemiologist Jamie Lopez-Bernal cautioned that low levels do not make the coming weeks easy to predict; the agency will continue monitoring the major respiratory viruses throughout winter.
The assessment follows UKHSA’s 8 October report that flu had been rising since August but remained at baseline, or very low, levels. September activity exceeded the corresponding period in each of the previous four winter seasons, suggesting a possible early season rather than confirming one.
Separately, UKHSA published FluSurvey findings on 15 October describing flu-like illness during the winters of 2023–24 and 2024–25. These are historical observations, not measurements of the current winter’s severity.
| Reported effect | Share | Respondents covered |
|---|---|---|
| Missed work or school because of symptoms | 47% | Symptomatic respondents in work or education |
| Sought help from a GP or another healthcare service |

The UK Health Security Agency says flu activity increased but remained low in the week of 2–8 November 2026, and expects a further rise as winter approaches.
Most respondents said illness disrupted their daily lives, but most treated their symptoms at home. The majority reported taking medication, most commonly painkillers. This helps explain why records from doctors and hospitals do not capture all the disruption caused by respiratory illness.
FluSurvey asks members of the public to report symptoms voluntarily each week, allowing it to record community illness that healthcare-based monitoring might miss. More than 68,000 weekly questionnaires were completed across the two winters. That is a count of surveys, not necessarily distinct people: participants can submit reports in multiple weeks. Nor is it a count of laboratory-confirmed flu cases.
The findings describe reported symptoms and their effects in those past winters. They do not establish how severe this winter will be or how well this season’s vaccine will work.
UKHSA’s first weekly winter respiratory-virus report covered 28 September–4 October, known as surveillance week 40. The agency said young adults were driving the increase; the Guardian’s 11 October report identified the age group as 18 to 24. Flu-test positivity is the share of tests that detect influenza.
| Measure | Reported level | Comparison |
|---|---|---|
| Flu-test positivity | 6.5% | 5% in the preceding reporting week |
| Flu hospitalisations | 1.97 per 100,000 people | No previous-week comparison: this surveillance formally began in week 40 |
England’s available subtyping data—tests that distinguish forms of influenza A—showed an equal mix of H3N2 and H1N1. Those early findings did not establish which virus would dominate the winter.
In its 8 October notice, UKHSA cited a World Health Organization technical report identifying an H1N1 virus recently seen at low levels in Europe and detected in the UK as genetically different from the H1N1 component used in this season’s vaccine. This change is called “drift”: the circulating virus has continued to evolve since the vaccine strain was selected.
Antonia Ho, a professor of infectious diseases at the University of Glasgow’s Centre for Virus Research, told the Guardian on 11 October that it was too soon to say whether the drift would affect vaccine effectiveness. She said the vaccine covers H1N1 and H3N2, the two influenza A subtypes circulating in England, as well as influenza B. UKHSA has not yet determined whether the drifted H1N1 virus will circulate widely in the UK or how effective the vaccine will be against it.
Andrew Pollard, director of the Oxford Vaccine Group, said an earlier season did not necessarily mean a worse one. He said the reasons for changes in timing were uncertain, suggesting a combination of weather, the circulating strain and its ability to spread, population immunity and behaviour such as close contact. Ho said an earlier start could mean a longer period of community transmission and more cases overall, but timing alone does not determine severity.
Nature’s 6 October report described unusually high flu-test positivity in the UK and on the US West Coast, and outbreaks that forced some Japanese schools to close in August and early September as pupils returned from summer break. University of Pennsylvania virologist Scott Hensley said an exceptionally early US season was possible if West Coast cases kept rising at the observed rate. Researchers cautioned that positive-test numbers were small compared with peak-season data, making the course difficult to predict.
In early US cases, H1N1 had replaced the previous season’s dominant subtype, H3N2. Seasonal flu involves these two influenza A subtypes and influenza B. Genetic changes in viruses, together with changes in people’s immunity through infection and vaccination, help explain why different viruses dominate different seasons.
| Virus | Reported finding |
|---|---|
| H1N1 | 96% of positive cases that underwent subtyping |
| H3N2 | Almost 4% of cases that underwent subtyping |
| Influenza B | Not detected |
Separately, University of Washington virologist Alex Greninger told Nature that his laboratory found an H1N1 mutation, or genetic change, called G155E in 13 of 17 samples with sufficiently complete genetic sequences. The samples came from Seattle hospitals and clinics in the months before the report; this small, local sample does not establish prevalence across the US.
A study led by Fred Hutchinson Cancer Center virologist Jesse Bloom, posted on bioRxiv in September before peer review, also flagged G155E. Researchers tested antibodies—immune proteins that recognise viruses—from 260 people in Australia and the US against 148 influenza A viruses circulating by mid-2026. They examined how well the antibodies recognised viruses and blocked infection.
Bloom said some, but not all, strains carrying G155E were less well recognised by existing antibodies, particularly those from teenagers and young adults. The researchers proposed that many people in those age groups had not encountered similar H1N1 viruses before; that remains a hypothesis. The laboratory findings do not establish more severe illness or vaccine failure.
Vaccine strains are selected several months before the season so manufacturers can produce supplies, while viruses can continue changing. UKHSA said vaccines typically still protect against severe flu when drifted strains occur. A drifted H3N2 virus dominated the previous winter, and the season started earlier, but overall cases and estimated mortality were lower than in the preceding season, the agency said.
UKHSA data reported by the Guardian on 11 October estimated that England’s vaccination programme prevented about 100,000 hospital admissions and 7,000 deaths in the previous winter. These modelling estimates do not measure this season’s vaccine effectiveness against drifted H1N1.
Nature’s 6 October report described Johns Hopkins epidemiologist Caitlin Rivers considering an earlier vaccination than her usual mid-to-late October timing, which she used to aim for protection around the usual US peaks in December and January. That was her personal strategy, not general advice. University of Oxford epidemiologist James Hay also cautioned that an early start need not mean a more severe season.
Lopez-Bernal urged eligible people to get vaccinated in UKHSA’s 8 October notice and renewed that advice on 15 October. The agency says eligible people can check eligibility and book free flu, COVID-19 or RSV vaccines through the NHS App, online, a GP practice or a participating pharmacy. RSV is respiratory syncytial virus. UKHSA also urged parents to ensure eligible children receive their nasal-spray flu vaccine.
UKHSA advises people with flu-like symptoms to stay at home, cover coughs and sneezes, practise good hand hygiene and avoid contact with particularly vulnerable people, including visits to those at greater risk in hospitals and care homes.
Weekly winter surveillance draws on reports from GPs, hospitals, laboratories and the wider community. UKHSA will continue tracking respiratory viruses throughout winter, and registration is open for people to join this season’s FluSurvey by completing one short symptom survey each week.
1 min